Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hurthle Cell Adenomas and Carcinomas).

Authors: Monaco, M  Chiappetta, G  Aiello, C  Federico, A  Sepe, R  Russo, D  Fusco, A  Pallante, P 
Citation: Monaco M, etal., Eur Thyroid J. 2014 Dec;3(4):211-6. doi: 10.1159/000367989. Epub 2014 Oct 15.
Pubmed: (View Article at PubMed) PMID:25759796
DOI: Full-text: DOI:10.1159/000367989

BACKGROUND: Previous analysis of CBX7 expression in a large number of thyroid adenoma and carcinoma samples revealed a progressive reduction of CBX7 levels that was well related with the malignant grade of thyroid neoplasias. Hurthle cell tumors are unusual thyroid neoplasms characterized by the presence of particular cells called oncocytes. OBJECTIVES: In order to develop new tools for a more accurate diagnosis of Hurthle cell tumors of the thyroid, we evaluated CBX7 protein levels to verify the possible presence of an expression signature. METHODS: CBX7 expression was evaluated by immunohistochemistry in a panel of thyroid tissue sections including normal thyroids, goiters, follicular adenomas and oncocytic lesions. RESULTS: CBX7 expression was low or null in 68% of Hurthle adenomas, whereas it was comparable to normal thyroid tissue in Hurthle hyperplasias and follicular adenomas. CONCLUSIONS: Reduced expression of CBX7 suggests a more aggressive identity of Hurthle adenomas with respect to non-Hurthle ones.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11352710
Created: 2016-07-15
Species: All species
Last Modified: 2016-07-15
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.